((自动化翻译由路透提供，请见免责声明 ))
1月7日 - ** 贝伦贝格在其 2025 年制药业展望中指出，肥胖症药物将成为管道新闻的主要内容，而中国的特定股票问题应开始缓解
** 贝伦贝格认为，肥胖症药物生产商的销售额将增长 26%，其中新兴的口服治疗药物将受到密切关注，而未涉足减肥治疗药物的生产商的销售额增长将放缓。
** 它还预计今年将出现并购热潮，约有 570 亿美元的未分配现金可供其覆盖的公司用于并购和业务发展。
** 很明显，研发预算正在增加，而外部管道资产仍是支持顶线的重要组成部分"--贝伦贝格
** 贝伦贝格补充道，一旦特朗普政府计划的可实现性得到更好的理解，与美国疫苗市场相关的股票应该会有所改善
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.